Trademark: INOSI 2303488
Word
INOSI
ID
2303488
Trademark Type
Word
Status
Registered: Registered/protected
Application Date
27 September 2022
Registration Date
27 September 2022
Renewal Date
27 September 2032
Owner(s)
Service
Inosi Therapeutics Pty Ltd
Goods and Services:
Class 5:
Chemical diagnostic reagents for medical use; Biochemical preparations for diagnostic use; Chemical products for pharmaceutical use; Pharmaceutical preparations; Pharmaceutical preparations for veterinary use; pharmaceutical preparations for use in the treatment of fibrosis, inflammatory and autoimmune disorders, metabolic diseases, cardiovascular diseases, liver fibrosis, kidney fibrosis, pulmonary fibrosis, vascular fibrosis and cardiac fibrosis; pharmaceutical preparations for use in the treatment of systemic sclerosis, Sjogren's syndrome, Rheumatoid arthritis, and systemic lupus erythematosus; pharmaceutical preparations for use in the treatment of cancer and radiation induced lung injury; pharmaceutical preparations for use in the treatment of idiopathic pulmonary fibrosis, and pulmonary arterial hypertension; pharmaceutical preparations for use in the treatment of nonalcoholic steatohepatitis (NASH), fatty liver diseases and disorders and steatohepatitis and other related diseases and disorders
Chemical diagnostic reagents for medical use; Biochemical preparations for diagnostic use; Chemical products for pharmaceutical use; Pharmaceutical preparations; Pharmaceutical preparations for veterinary use; pharmaceutical preparations for use in the treatment of fibrosis, inflammatory and autoimmune disorders, metabolic diseases, cardiovascular diseases, liver fibrosis, kidney fibrosis, pulmonary fibrosis, vascular fibrosis and cardiac fibrosis; pharmaceutical preparations for use in the treatment of systemic sclerosis, Sjogren's syndrome, Rheumatoid arthritis, and systemic lupus erythematosus; pharmaceutical preparations for use in the treatment of cancer and radiation induced lung injury; pharmaceutical preparations for use in the treatment of idiopathic pulmonary fibrosis, and pulmonary arterial hypertension; pharmaceutical preparations for use in the treatment of nonalcoholic steatohepatitis (NASH), fatty liver diseases and disorders and steatohepatitis and other related diseases and disorders